ILLUMINA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121.2 USD | -4.65% |
|
-6.89% | -12.98% |
| 11:31am | ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca |  |
| 11:17am | Baptista Research Downgrades Illumina to Hold From Buy, Adjusts PT to $149.60 From $145 | MT |
Financials (USD)
| Sales 2024 * | 4.52B | Sales 2025 * | 4.96B | Capitalization | 19.3B |
|---|---|---|---|---|---|
| Net income 2024 * | -114M | Net income 2025 * | 271M | EV / Sales 2024 * | 4.27 x |
| Net Debt 2024 * | 23.8M | Net cash position 2025 * | 770M | EV / Sales 2025 * | 3.73 x |
| P/E ratio 2024 * |
-204
x | P/E ratio 2025 * |
62.4
x | Employees | 10,615 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Illumina, Inc.
More recommendations
More press releases
More news
| 1 day | -4.65% | ||
| 1 week | -6.89% | ||
| Current month | -11.77% | ||
| 1 month | -5.14% | ||
| 3 months | -12.23% | ||
| 6 months | -6.16% | ||
| Current year | -12.98% |
1 week
120.97
134.85
1 month
120.97144.19
Current year
120.97148.19
1 year
89.00232.23
3 years
89.00526.00
5 years
89.00555.77
10 years
89.00555.77
| Managers | Title | Age | Since |
|---|---|---|---|
Jacob Thaysen
CEO | Chief Executive Officer | 49 | 23-09-24 |
Steven Barnard
CTO | Chief Tech/Sci/R&D Officer | - | 97-12-31 |
Carissa Rollins
CTO | Chief Tech/Sci/R&D Officer | 54 | 22-03-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 12-11-28 |
| Chairman | 60 | 23-06-01 | |
Caroline Dorsa
BRD | Director/Board Member | 64 | 17-01-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.11% | 2 M€ | -.--% | ||
| 3.62% | 1 M€ | -1.52% | - | |
| 3.11% | 0 M€ | 0.00% | - | |
| 3.03% | 0 M€ | 0.00% | - | |
| 1.77% | 2 M€ | -25.75% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 121.2 | -4.65% | 1,616,891 |
| 24-04-12 | 127.1 | -2.78% | 1,629,452 |
| 24-04-11 | 130.7 | -0.36% | 1,085,355 |
| 24-04-10 | 131.2 | -1.80% | 1,868,993 |
| 24-04-09 | 133.6 | +2.65% | 1,735,440 |
Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT
More quotes
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
160.7
USD
Spread / Average Target
+32.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.98% | 19.3B | |
| +5.10% | 213B | |
| +3.60% | 177B | |
| +11.86% | 134B | |
| +16.66% | 99.13B | |
| +1.03% | 63.47B | |
| +16.98% | 53.69B | |
| -4.51% | 46.36B | |
| +0.86% | 41.09B | |
| +11.39% | 39.3B |
- Stock Market
- Equities
- ILMN Stock
